Joanna Horobin

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer

David E. Gerber, D. Ross Camidge, Daniel Morgensztern et al. · Lung Cancer · 2019 · 182 citations · Full text

Medicine, Oncology, Pharmacology +12

A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

Toshio Shimizu, Kazuya Fukuoka, Masayuki Takeda et al. · Cancer Chemotherapy and Pharmacology · 2016 · 109 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer.

Manish R. Patel, Jeffrey R. Infante, Kathleen N. Moore et al. · Journal of Clinical Oncology · 2014 · 29 citations

Medicine, Oncology, Pharmacology +17